Back to top
more

GENFIT (GNFT)

(Delayed Data from NSDQ)

$3.49 USD

3.49
1,426

+0.04 (1.16%)

Updated Apr 26, 2024 11:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GNFT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

GENFIT S.A. Unsponsored ADR [GNFT]

Reports for Purchase

Showing records 1 - 20 ( 113 total )

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

12/08/2023

Company Report

Pages: 12

Three Regulatory Filings For Elafibranor in PBC Submitted; We Look For Progress Across ACLF Programs in 2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

09/21/2023

Company Report

Pages: 8

1H23 Recap; First Elafibranor PBC Regulatory Filing Expected By Year-End 2023; Pipeline Expansion Continues; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

07/03/2023

Company Report

Pages: 8

Positive ELATIVE Phase 3 Dataset Supports Elafibranor''s Potential U.S. Approval For PBC in 2H24; Increasing PT to $11

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 4

06/01/2023

Daily Note

Pages: 3

GENFIT Acquires Global Rights to ASK1 Inhibitor For ACLF; Phase 3 ELATIVE PBC Data Expected in June; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 5

05/24/2023

Daily Note

Pages: 4

Journal of Hepatology Highlights Potential of NIS2+ as NASH Diagnostic Tool in Clinical Trials; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 6

04/17/2023

Company Report

Pages: 10

FY22 Recap; Top-line Phase 3 PBC Readout in June; Adding ACLF, CCA Programs to Model; Raise PT to $9; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 7

01/20/2023

Company Report

Pages: 6

GNS561 Granted Orphan Drug Designation For HCC; Phase 3 ELATIVE Readout in 2Q23 Represents Key Catalyst; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 8

09/29/2022

Company Report

Pages: 8

1H22 Recap; GENFIT''s Pipeline Now Has Six Programs; Phase 3 ELATIVE PBC Top-Line Data On Target in 2Q23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 9

09/20/2022

Daily Note

Pages: 4

GENFIT Adds Two Key Assets to Its Liver Disease Pipeline With Versantis Acquisition; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 10

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 11

04/13/2022

Company Report

Pages: 9

2H21 Recap; ELATIVE Close to Complete Enrollment; Top-Line Readout on Target in 2Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 12

12/20/2021

Company Report

Pages: 8

GENFIT Signs Two Transformative Deals; Upgrading Our Rating to Buy With $8 PT on a Renewed Outlook

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 13

09/30/2021

Company Report

Pages: 8

1H21 Recap; Phase 3 ELATIVE Timeline Slightly Delayed by COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 14

04/05/2021

Company Report

Pages: 8

FY20 Recap; GENFIT Continues Its Transition in 2021 As Phase 3 ELATIVE PBC Trial Continues; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 15

03/01/2021

Daily Note

Pages: 4

YE20 Pro-Forma Cash Roughly $150M; Full Year 2020 Results Expected on April 1; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 16

02/17/2021

Company Report

Pages: 7

PBC KOL Event Highlights Elafibranor''s Opportunity in Second-Line PBC Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 17

01/26/2021

Daily Note

Pages: 3

Approval of OCEANE Buyback and Amendments to Improve Financial Maneuverability; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 18

12/07/2020

Daily Note

Pages: 3

Completion of OCEANE Buyback And Terms Amendment Set for Late January; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 19

11/23/2020

Daily Note

Pages: 3

We Expect OCEANE Buybacks and Amendments to Improve Financial Flexibility; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 20

11/16/2020

Daily Note

Pages: 3

Draining the OCEANE to Reach ELATIVE

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party